Androgen receptor signaling inhibitors associated with Increased cardiovascular risks ,warns study Jacinthlyn Sylvia19 Jun 2024 4:45 PMCardiovascular (CV) events remain a significant cause of mortality among men with advanced and metastatic prostate cancer (PCa). A recent study...
Reduced PSA Screening Rates Associated with Rise in Metastatic Prostate Cancer: JAMA Dr. Kamal Kant Kohli30 Oct 2022 2:30 PMSAN ANTONIO: A recent study reported in JAMA Oncology revealed that lower prostate-specific antigen (PSA) screening rates were linked to later higher...
Prostate RT improves overall survival in men with newly diagnosed, low-burden metastatic prostate cancer Dr. Hiral patel24 Jun 2022 2:30 PMUK: In men with newly diagnosed, low-burden metastatic prostate cancer, Prostate radiotherapy RT improves overall survival (OS), without detriment in...
Bayer gets USFDA priority review for darolutamide plus docetaxel to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma4 May 2022 6:30 AMDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Darolutamide added to existing combination therapy in metastatic prostate cancer increases survival, NEJM says Medical Dialogues Editorial Team22 Feb 2022 3:30 AMIn a new trial overall survival was remarkably longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with...
Bayer lifts peak sales estimate for prostate cancer drug Nubeqa : Report Ruchika Sharma18 Feb 2022 4:30 AMFrankfurt: A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer...
Amneal Pharma launches Abiraterone Acetate Tablets post USFDA nod Ruchika Sharma9 Jan 2021 10:13 AMBridgewater: Amneal Pharmaceuticals has recently announced that the company has received approval of an additional strength of 500 mg to its...
PARPi olaparib increases survival rate of metastatic prostate cancer, finds study Hina Zahid25 Sept 2020 11:45 AMResults from the PROfound phase III study, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with...
